About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Likang gets trial ok for China’s first personalized cancer vaccine 

Purple Biotech sees positive results from cancer study

How cancer cells repair DNA damage from radiotherapy

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Mediar Therapeutics boosts fibrosis portfolio with $105M financing

ADVERTISEMENT

Nanite receives funding to deliver genetic therapies to the lungs

Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Astellas menopause study meets endpoints but leukemia drug disappoints

How the microbiome can predict cancer immunotherapy success

Calliditas shares rise as phase 3 endpoints met in kidney disease trial

ADVERTISEMENT